The preoperative platelet to albumin ratio predicts the prognosis of hepatocellular carcinoma patients without portal hypertension after liver resection

Li, Chuan; Peng, Wei; Zhang, Xiaoyun; Wen, Tianfu; Li-ping, Chen

doi:10.1097/md.0000000000017920

Cited by 18 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver fibrosis and the platelet-to-albumin ratio ( Figure 3B ) are important indicators of liver inflammation, which results in impaired antitumor immune response ( 5 , 32 ). Therefore, the association between TBK1 expression and degree of immune infiltration in HCC was further investigated in this study.…”

Section: Resultsmentioning

confidence: 99%

TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration

Jiang

Chen

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundNumerous cancer types present the aberrant TANK-binding kinase 1 (TBK1) expression, which plays an important role in driving inflammation and innate immunity. However, the prognostic role of TBK1 and its relationship with immune cell infiltration in hepatocellular carcinoma (HCC) remain unclear.MethodsThe expression and prognostic value of TBK1 was analyzed by Tumor Immune Estimation Resource (TIMER), Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis (GEPIA), Clinical Proteomic Tumor Analysis Consortium (CPTAC) and further confirmed in the present cohort of patients with HCC. The association between TBK1 and HCC immune infiltrates, and its potential mechanism were investigated via analyses of the Tumor Immune Estimation Resource, tumor-immune system interactions database (TISIDB), CIBERSORT, STRING, and Metascape. The effect of TBK1 on immune infiltrates and the therapeutic value of targeting TBK1 were further investigated in a HCC mouse model by treatment with a TBK1 antagonist.ResultsThe level of TBK1 expression in HCC was higher than that measured in normal tissues, and associated with poorer overall survival (GEPIA: hazard ratio [HR]=1.80, P=0.038; Kaplan–Meier plotter: HR=1.87, P<0.001; CPTAC: HR=2.23, P=0.007; Our cohort: HR=2.92, P=0.002). In addition, high TBK1 expression was found in HCC with advanced TNM stage and identified as an independent poor prognostic factor for overall survival among patients with HCC. In terms of immune infiltration, tumor tissues from HCC patients with high TBK1 expression had a low proportion of CD8+ T cells, and TBK1 expression did not show prognostic value in HCC patients with enriched CD8+ T cells. Furthermore, TBK1 expression was positively correlated with the markers of T cell exhaustion and immunosuppressive cells in the HCC microenvironment. Mechanistically, the promotion of HCC immunosuppression by TBK1 was involved in the regulation of inflammatory cytokines. In vivo experiments revealed that treatment with a TBK1 antagonist delayed HCC growth by increasing the number of tumor-infiltrating CD8+ T cells.ConclusionsThe up-regulated expression of TBK1 may be useful in predicting poor prognosis of patients with HCC. In addition, TBK1, which promotes the HCC immunosuppressive microenvironment, may be a potential immunotherapeutic target for patients with HCC.

show abstract

Section: Resultsmentioning

confidence: 99%

TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration

Jiang

Chen

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Yet, present outcomes seem, by all accounts, to be in good congruency with those previously reported for pancreatic adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, and non-small cell lung carcinoma patients undergoing surgery. [18][19][20][21] Guo et al 21 in a group of 198 stage I-IV non-small cell lung cancer patients who underwent thoracic surgery found that the preoperative PAR>8.8 was an independent predictor of significantly worse median OS times (P<0.001). Likewise, in the largest ever PAR study, Li et al 20 reported that patients with high preoperative PAR (>4.8) had a higher recurrence risk and lower longterm survival chance than those with low PAR in a total of 628 hepatocellular carcinoma patients treated with liver resection.…”

Section: Discussionmentioning

confidence: 99%

“…[18][19][20][21] Guo et al 21 in a group of 198 stage I-IV non-small cell lung cancer patients who underwent thoracic surgery found that the preoperative PAR>8.8 was an independent predictor of significantly worse median OS times (P<0.001). Likewise, in the largest ever PAR study, Li et al 20 reported that patients with high preoperative PAR (>4.8) had a higher recurrence risk and lower longterm survival chance than those with low PAR in a total of 628 hepatocellular carcinoma patients treated with liver resection. The remaining two studies in pancreatic cancer and cholangiocarcinoma patients further confirmed the poor prognostic characteristic of the high preoperative PAR values in these tumor primaries, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…18 Past investigations on the prognostic worth of PAR showed that the preoperative PAR was robustly associated with the patients' prognoses in pancreatic adenocarcinomas, cholangiocarcinomas, hepatocellular carcinomas, and non-small cell lung carcinomas, as well as the malignant melanomas undergoing 1 surgery. [18][19][20][21] To our best data, though the amassed proof proposes a respectable independent prognostic power for PAR in prediction of the outcomes of patients with various cancers, to date, no study has explored the prognostic worth of pre-CCRT PAR in LANPC patients treated with definitive CCRT. Therefore, the present retrospective cohort investigation was planned to uncover the plausible prognostic usefulness of pre-CCRT PAR measures in LANPC patients treated with radical CCRT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy

Haksöyler¹,

Topkan²

2021

TCRM

View full text Add to dashboard Cite

In a lack of similar research, we assessed the prognostic utility of pretreatment platelet-to-albumin ratio (PAR) in locally advanced nasopharyngeal carcinoma (LANPC) patients managed with concurrent chemoradiotherapy (CCRT). Patients and Methods: Present retrospective analysis included a sum of 128 consecutively treated LANPC patients who underwent cisplatinum-based radical CCRT. Availability of an ideal pretreatment PAR cutoff that may stratify the study population into two cohorts with significantly distinct survival outcomes was sought by utilizing the receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. Results: A rounded 5.2 [area under the curve (AUC): 68.9%; sensitivity: 67.4%; and specificity: 65.2%] value was identified as the ideal PAR cutoff that grouped patients into two gatherings [PAR≥5.2 (N=60) versus <5.2 (N=68)]. The median follow-up duration was 86.4 months (range: 9-147). Kaplan-Meier comparisons between the two PAR groups revealed significantly diminished median PFS (69.4 versus 106.8 months for PAR<5.2; P< 0.012) and OS (88.3 versus not reached yet for PAR<5.2; P= 0.023) for the PAR ≥ 5.2 group. The results of multivariate analyses affirmed the pretreatment PAR≥5.2 as an independent prognostic factor that indicates diminished PFS (P= 0.016) and OS (P= 0.019) together with the respective N 2-3 nodal stage (versus N 0-1 ; P<0.05 for PFS and OS, respectively) and weight loss >5% at past six months (≤5%; P<0.05 for PFS and OS, respectively). Conclusion:The results of the current retrospective analysis provided a robust and independent adverse prognostic value for pretreatment PAR ≥ 5.2 in terms of median and longterm PFS and OS outcomes in LA-NPC patients this patient group treated with conclusive CCRT.

show abstract

“…In recent years, the prediction model of prognosis of the HCC combined with different in ammation factors has always been a hot issue [9,10,29,30]. Previous studies have examined GLR's prognostic ability in HCC [14,31], intrahepatic cholangiocarcinoma [32] and nonfunctional pancreatic neuroendocrine tumors [25].…”

Section: Discussionmentioning

confidence: 99%

Non-Linear Relationship of Gamma-Glutamyl Transpeptidase To Lymphocyte Count Ratio With The Recurrence of Hepatocellular Carcinoma with Staging I-II: A Retrospective Cohort Study

Liang

Wen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background high recurrence rate was a major factor for poor postoperative prognosis of hepatocellular carcinoma (HCC) patients. The present study was intended to evaluate the association of gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) and the recurrence of HCC with staging I-II in Chinese. Methods the retrospective cohort data was derived from the First Affiliated Hospital of Zhengzhou University from January 2014 to December 2018 on 496 patients who underwent radical resection of HCC with staging I-II. Multivariable Cox regression models were used to determine hazard ratios (HR) and 95% confidence intervals (CIs) for the recurrence of HCC with staging I-II of each GLR tertile category. The restricted cubic spline model was used to find out the threshold effect. Results with the low tertile of GLR as the reference, multivariable-adjusted HRs and 95% CIs of the middle and high tertile categories were 1.748 (1.170, 2.612) and 2.078 (1.339, 3.227). In addition, there was a positive correlation (1.002 (1.001, 1.004)) and a non-liner relationship was found, whose point was 27.5. When the GLR was less than 27.5, the risk of recurrence increased, obviously with the increase in GLR levels (1.041 (1.014, 1.068)). Conclusions the GLR was independently associated with the recurrence of HCC patients with staging I-II. Furthermore, the relationship was positive and no-linear.

show abstract

The preoperative platelet to albumin ratio predicts the prognosis of hepatocellular carcinoma patients without portal hypertension after liver resection

Cited by 18 publications

References 42 publications

TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration

TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration

High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy

Non-Linear Relationship of Gamma-Glutamyl Transpeptidase To Lymphocyte Count Ratio With The Recurrence of Hepatocellular Carcinoma with Staging I-II: A Retrospective Cohort Study

Contact Info

Product

Resources

About